NPI: 1255429338 · HOOD RIVER, OR 97031 · Critical Access Hospital · NPI assigned 10/11/2006
Authorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
| Authorized Official | ANDERSON, DONALD (ASSISTANT SECRETARY ENROLLMENTS) |
| Parent Organization | PROVIDENCE HEALTH & SERVICES OREGON |
| NPI Enumeration Date | 10/11/2006 |
Other providers sharing the same authorized official: ANDERSON, DONALD
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 19,390 | $1.79M |
| 2019 | 8,119 | $868K |
| 2020 | 5,196 | $502K |
| 2021 | 7,675 | $856K |
| 2022 | 10,464 | $1.46M |
| 2023 | 8,889 | $1.65M |
| 2024 | 7,323 | $1.65M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 17,112 | 11,313 | $4.14M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 9,665 | 6,607 | $2.85M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2,468 | 1,597 | $704K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1,655 | 1,168 | $89K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 103 | 100 | $82K |
| 80053 | Comprehensive metabolic panel | 5,996 | 5,104 | $75K |
| 96361 | Intravenous infusion, hydration; each additional hour | 379 | 313 | $71K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 7,710 | 6,484 | $65K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2,493 | 1,416 | $52K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 883 | 809 | $49K |
| 96375 | Therapeutic injection; each additional sequential IV push | 688 | 568 | $45K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 321 | 271 | $42K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1,508 | 915 | $38K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 15 | 12 | $36K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 152 | 149 | $35K |
| 71046 | Radiologic examination, chest; 2 views | 517 | 486 | $31K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 129 | 106 | $24K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 204 | 129 | $24K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 381 | 352 | $21K |
| J7050 | Infusion, normal saline solution, 250 cc | 1,307 | 731 | $17K |
| J7120 | Ringers lactate infusion, up to 1000 cc | 610 | 548 | $15K |
| J7030 | Infusion, normal saline solution , 1000 cc | 541 | 451 | $15K |
| 84443 | Thyroid stimulating hormone (TSH) | 349 | 332 | $12K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 97 | 65 | $12K |
| 81001 | 2,072 | 1,889 | $11K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 90 | 88 | $11K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 67 | 62 | $11K |
| 59025 | Fetal non-stress test | 48 | 39 | $11K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 46 | 45 | $11K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 15 | 15 | $9K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 955 | 779 | $9K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 36 | 35 | $9K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 361 | 304 | $8K |
| 36415 | Collection of venous blood by venipuncture | 1,381 | 1,170 | $7K |
| 80061 | Lipid panel | 233 | 226 | $7K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 210 | 194 | $6K |
| 80048 | Basic metabolic panel (calcium, ionized) | 444 | 411 | $6K |
| 84484 | 94 | 84 | $6K | |
| 85027 | 697 | 627 | $6K | |
| 83690 | 275 | 243 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 221 | 208 | $5K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 232 | 212 | $5K |
| J2704 | Injection, propofol, 10 mg | 249 | 241 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 240 | 213 | $4K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 85 | 78 | $4K |
| 81025 | 425 | 394 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 103 | 100 | $4K |
| 70450 | Computed tomography, head or brain; without contrast material | 12 | 12 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 103 | 100 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 209 | 172 | $3K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 60 | 60 | $3K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 16 | 12 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 182 | 172 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | 74 | 61 | $3K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 385 | 370 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 47 | 40 | $2K |
| 76830 | Ultrasound, transvaginal | 19 | 19 | $2K |
| 85610 | 203 | 119 | $2K | |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 18 | 12 | $2K |
| 84439 | 66 | 64 | $2K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 13 | 12 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 108 | 100 | $2K |
| 86803 | 73 | 70 | $2K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 97 | 92 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 479 | 455 | $1K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 36 | 36 | $1K |
| 87081 | 66 | 66 | $1K | |
| 83516 | 84 | 79 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 13 | 12 | $874.69 |
| 73610 | 13 | 12 | $868.24 | |
| 87070 | 43 | 42 | $769.45 | |
| 80305 | 86 | 75 | $760.67 | |
| 92567 | 14 | 13 | $750.20 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 32 | 25 | $749.36 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 31 | 27 | $748.82 |
| J2060 | Injection, lorazepam, 2 mg | 28 | 26 | $712.12 |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 80 | 73 | $698.89 |
| 86850 | 60 | 57 | $671.25 | |
| 88142 | 29 | 28 | $665.97 | |
| 86900 | 82 | 73 | $635.32 | |
| 81003 | 71 | 67 | $604.11 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 16 | 14 | $573.83 |
| 87340 | 36 | 36 | $497.90 | |
| 96376 | 18 | 14 | $438.34 | |
| 86901 | 82 | 73 | $437.62 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 12 | 12 | $257.92 |
| 87510 | 15 | 14 | $250.54 | |
| 87660 | 15 | 14 | $219.62 | |
| 87480 | 15 | 14 | $214.22 | |
| 87186 | 13 | 12 | $212.06 | |
| 85652 | 12 | 12 | $207.27 | |
| 82950 | 13 | 12 | $202.58 | |
| 82247 | 15 | 14 | $38.56 |